Drug Profile
Belvarafenib - Genentech/Hanmi Pharmaceutical
Alternative Names: GDC 5573; HM-95573; RG 6185Latest Information Update: 15 Feb 2024
Price :
$50
*
At a glance
- Originator Hanmi Pharmaceutical
- Developer Genentech; Hanmi Pharmaceutical
- Class Amides; Antineoplastics; Pyrimidines; Small molecules
- Mechanism of Action Proto oncogene protein b raf inhibitors; Proto oncogene proteins c raf inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Solid tumours
- Phase I Malignant melanoma
Most Recent Events
- 15 Feb 2024 Belvarafenib is still in phase-I trials for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in South Korea (Roche pipeline, February 2024), (NCT03284502)
- 09 Dec 2023 Pharmacodynamics data from a preclinical trial in Acute myeloid leukemia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 20 Oct 2023 Efficacy and adverse events data from a phase Ib trial in Malignant melanoma presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)